Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection

Hepatology

Volumn 60, Issue 2, 2014, Pages 487-496

  Riva, Antonio ^a   Laird, Melissa ^b,c   Casrouge, Armanda ^b,c   Ambrozaitis, Arvydas ^d   Williams, Roger ^a   Naoumov, Nikolai ^a   Albert, Matthew ^b,c,e   Chokshi, Shilpa ^a  

^a INSTITUTE OF HEPATOLOGY   (United Kingdom)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

^d VILNIUS UNIVERSITY   (Lithuania)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 15;

ADAPTIVE IMMUNITY; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INNATE IMMUNITY; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS DETECTION;

ADAPTIVE IMMUNITY; ADULT; CHEMOKINE CXCL10; DIPEPTIDYL PEPTIDASE 4; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; INTERLEUKIN-10; KILLER CELLS, NATURAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84904734203     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27139     Document Type: Article

References (37)

1. WHO Hepatitis C [Internet]. WHO. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
2. Pachiadakis I, Chokshi S, Cooksley H, Farmakiotis D, Sarrazin C, Zeuzem S, et al. Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Clin Immunol 2009;131:415-425.
3. Della Bella S, Crosignani A, Riva A, Presicce P, Benetti A, Longhi R, et al. Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology 2007;121:283-292.
4. Tang KH, Herrmann E, Cooksley H, Tatman N, Chokshi S, Williams R, et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol 2005;43:776-782.
5. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000;118:346-355.
6. Ragab D, Laird M, Duffy D, Casrouge A, Mamdouh R, Abass A, et al. CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine 2013;63:105-112.
7. Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski ER, Chokshi S, et al. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection. J Viral Hepat 2012;19:501-508.
8. Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, et al. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol 2011;55:545-553.
9. + T cells causes the late onset of acute hepatitis C. Gastroenterology 2011;141:686-695, 695.e1.
10. Brownell J, Bruckner J, Wagoner J, Thomas E, Loo Y-M, Gale M Jr, et al. Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection. J Virol 2014;88:1582-1590.
11. Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013;57:2124-2134.
12. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky J-M, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006;194:895-903.
13. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011;121:308-317.
14. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001;98:3554-3561.
15. Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, et al. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob Agents Chemother 2008;52:312-320.
16. Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol 2012;57:1349-1360.
17. Rehermann B, Naoumov N. Immunological techniques in viral hepatitis. J Hepatol 2007;46:508-520.
18. Koziel MJ. NK cells: natural born killers in the conflict between humans and HCV. Hepatology 2006;43:395-397.
19. Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, et al. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008;198:1749-1755.
20. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006;20:123-137.
21. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005;22:295-304.
22. Meier U-C, Owen RE, Taylor E, Worth A, Naoumov N, Willberg C, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol 2005;79:12365-12374.
23. Wuttge DM, Wildt M, Geborek P, Wollheim FA, Scheja A, Akesson A. Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease. Arthritis Res Ther 2007;9:R85.
24. Lamana A, Ortiz AM, Alvaro-Gracia JM, Díaz-Sánchez B, Novalbos J, García-Vicuña R, et al. Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker. Eur Cytokine Netw 2010;21:186-194.
25. Al-Ashgar HI, Khan MQ, Helmy A, Al-Thawadi S, Al-Ahdal MN, Khalaf N, et al. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4. Eur J Gastroenterol Hepatol 2013;25:404-410.
26. Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012;142:78-85.e2.
27. Söderholm J, Waldenström J, Askarieh G, Pilli M, Bochud P-Y, Negro F, et al. Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. PLoS ONE 2013;8:e56991.
28. Chan S-C, Lo S-Y, Liou J-W, Lin M-C, Syu C-L, Lai M-J, et al. Visualization of the structures of the hepatitis C virus replication complex. Biochem Biophys Res Commun 2011;404:574-578.
29. Bohannon N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med 2009;121:40-45.
30. Brady MT, MacDonald AJ, Rowan AG, Mills KHG. Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol 2003;33:3448-3457.
31. Oliviero B, Mele D, Degasperi E, Aghemo A, Cremonesi E, Rumi MG, et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol 2013;59:38-44.
32. Maghazachi AA. Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol 2010;341:37-58.
33. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001;166:6477-6482.
34. Chan A, Hong D-L, Atzberger A, Kollnberger S, Filer AD, Buckley CD, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007;179:89-94.
35. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005;86:209-239.
36. Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thélu M-A, Sturm N, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 2009;51:458-467.
37. Tarazona R, Casado JG, Delarosa O, Torre-Cisneros J, Villanueva JL, Sanchez B, et al. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 2002;22:176-183.